Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management
Current Oncology · 2023
DOI: 10.3390/curroncol30030230 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Tzu-Fei Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Immunological, Lung Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) target programmed cell death (PD) 1 receptor and its ligand PD-L1, and have become an integral part of treatment regimens in many cancers including lung cancer, renal cell carcinoma, melanoma, and more. Cancer is associated with a significantly increased risk of venous thromboembolism compared to non-cancer patients, and the risks increase further with anticancer therapies including ICIs. Cancer-associated thrombosis can lead to hospitalizations, delayed cancer treatment, and mortality. While thrombosis was not reported as a major complication in initial clinical trials leading to the approval of ICIs, emerging evidence from post-marketing studies revealed concerning risks of thrombosis in patients receiving ICIs. However, results remained heterogenous given differences in study designs and populations. Recent studies also showed that C-reactive protein dynamics might be an easily accessible biomarker for thrombosis and disease response in this population. In addition, early findings indicated that a commonly used anticoagulant for cancer-associated thrombosis, factor Xa inhibitors, might have potential synergistic antitumor effects when combined with ICIs. Herein we will review the current literature on the incidence, risk factors, and management of thrombosis in patients with cancer receiving ICIs. We aim to provide valuable information for clinicians in managing these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
ORCID-Profile: Tzu-Fei Wang, Marc Carrier
Zitieren
APA
Wang, T. F., & Carrier, M. (2023). Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management. Current Oncology. https://doi.org/10.3390/curroncol30030230
Vancouver
Wang TF, Carrier M. Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management. Current Oncology. 2023. doi:10.3390/curroncol30030230
BibTeX
@article{Wang2023,
author = {Wang, Tzu-Fei and Carrier, Marc},
title = {Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30030230}
}
EUVIMED